SCHEMBL4861973

SCHEMBL4861973

Cc1cc(I)ccc1Nc1c(C(=O)O)cc(Cl)c(F)c1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 6/20 0.59
MAP2K2 P36507 3/20 0.53
IDO1 P14902 3/20 0.50
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
TDP1 Q9NUW8 1/20 0.49
MAPK1 P28482 1/20 0.48
AURKA O14965 3/20 0.45
TNFRSF1A P19438 3/20 0.45
MAP3K9 P80192 2/20 0.45
KDR P35968 1/20 0.45
CLCN2 P51788 2/20 0.44
SRC P12931 2/20 0.43
PRKCB P05771 1/20 0.43
STK3 Q13188 1/20 0.43
ABL1 P00519 1/20 0.42
LCK P06239 1/20 0.42
CLK1 P49759 1/20 0.42
GFER P55789 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24849049 0.88 MAP2K1 (0.56) MAP2K1MAP2K2IDO1MEN1KMT2A
SCHEMBL5872850 0.88 MAP2K1 (0.56) MAP2K1MAP2K2IDO1MEN1KMT2A
SCHEMBL4861572 0.88 MAP2K1 (0.74) MAP2K1MAP2K2IDO1AURKATNFRSF1A
SCHEMBL5400394 0.88 MEN1 (0.53) MAP2K1MAP2K2IDO1MEN1KMT2A
SCHEMBL4853895 0.87 MEN1 (0.62) MAP2K1MAP2K2IDO1MEN1KMT2A
SCHEMBL4861840 0.87 MAP2K1 (0.70) MAP2K1MAP2K2IDO1AURKATNFRSF1A
SCHEMBL2387610 0.85 MAP2K1 (0.53) MAP2K1MAP2K2IDO1MEN1KMT2A
SCHEMBL4860826 0.85 MEN1 (0.50) MAP2K1MAP2K2IDO1MEN1KMT2A
SCHEMBL23693639 0.83 MAP2K1 (0.51) MAP2K1MAP2K2IDO1MEN1KMT2A
SCHEMBL29425442 0.83 MAP2K1 (0.51) MAP2K1MAP2K2IDO1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140062-B1 TREATMENT OF ASTHMA WITH MEK INHIBITORS WARNER LAMBERT CO (US) 2005-04-06 EP claimed
US-6696440-B1 ADMINISTERING MITOGEN ACTIVATED PROTEIN KINASE(MEK) INHIBITORS COMPRISING SECONDARY CARBOCYCLIC AMINES, AS ANTIASTHMATIC AGENTS WARNER-LAMBERT COMPANY 2004-02-24 US claimed
JP-2003504400-A 2003-02-04 JP claimed
JP-2002532414-A 2002-10-02 JP claimed
JP-2002532415-A 2002-10-02 JP claimed
EP-1202726-A2 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-05-08 EP claimed
EP-1143957-A3 TREATMENT OF ARTHRITIS WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-02-27 EP claimed
EP-1143957-A2 TREATMENT OF ARTHRITIS WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-10-17 EP claimed
EP-1140046-A1 USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION WARNER-LAMBERT COMPANY (US) 2001-10-10 EP claimed
EP-1140067-A1 ANTIVIRAL METHOD USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-10-10 EP claimed
EP-1140062-A2 TREATMENT OF ASTHMA WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-10-10 EP claimed
WO-2000035435-A9 USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION WARNER LAMBERT CO (US) 2001-03-22 WO claimed
WO-2001005392-A2 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-01-25 WO claimed
WO-2000040235-A2 TREATMENT OF ASTHMA WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-07-13 WO claimed
WO-2000040237-A1 ANTIVIRAL METHOD USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-07-13 WO claimed
WO-2000035435-A1 USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION WARNER-LAMBERT COMPANY (US) 2000-06-22 WO claimed
WO-2000035436-A2 TREATMENT OF ARTHRITIS WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-06-22 WO claimed
EP-1301472-B1 OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS WARNER LAMBERT CO (US) 2014-03-26 EP disclosed
WO-2000035435-A1 USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION WARNER-LAMBERT COMPANY (US) 2000-06-22 WO disclosed
WO-2000035436-A2 TREATMENT OF ARTHRITIS WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-06-22 WO disclosed